Connecticut

Biohaven’s migraine progress pays off with a Pfizer marketing pact for two drugs

Biohaven Pharmaceuticals has seen strong U.S. market uptake for its oral migraine drug, Nurtec. With regulatory decisions looming around the world, the company has landed the marketing muscle of Pfizer, which is paying $500 million up front for the right to market that drug and another clinical-stage compound outside of the U.S.

Specialty physicians in Connecticut gain path to value-based care, payment boost via private health plan

The State of Connecticut Health Plan is the first commercial plan in the country to have its episodes-of-care payment model designated as an Advanced APM by CMS. This will provide specialty physicians in the state a path to value-based care payments through the private sector, as their Advanced APM options via CMS are limited.

State of Connecticut’s New ‘Episodes-of-Care Health Plan’ Could Be Key to Scaling Value-Based Care

By JESSICA DaMASSA, WTF HEALTH Signify Health (NYSE: SGFY) has called their approach “Value-Based Care 2.0” and, today, they’ve received an important designation from CMS that could set an exciting precedent for scaling up episodes-of-care, value-based models for the under 65 commercial health insurance market. The plan to receive this important approval as an Advanced …

State of Connecticut’s New ‘Episodes-of-Care Health Plan’ Could Be Key to Scaling Value-Based Care Read More »

Biohaven drug licensed from AstraZeneca fails Phase 3 test in rare neuro disorder

Biohaven’s bet on an AstraZeneca drug for multiple system atrophy does not pan out, failing a pivotal study in the rare, neurodegenerative disorder. But a separate Phase 3 study evaluating verdiperstat in amyotrophic lateral sclerosis is still moving forward.

FDA approves first drug for severe itching in chronic kidney disease patients

Chronic kidney disease patients who experience pruritus after dialysis can now get relief from the first FDA-approved treatment for the condition. Cara Therapeutics received the FDA’s nod green light for its injectable drug, Korsuva.

Pfizer commits $1B to Arvinas for share of protein degrading breast cancer drug

Arvinas’ early clinical data for its targeted protein degradation drug for breast cancer drew partnering interest from several companies. Pfizer beat them all with a deal that pays the biotech $1 billion to share in the development and commercialization of this therapy.

Zooming Into the Statehouse: Nursing Home Residents Use New Digital Skills to Push for Changes

Patty Bausch isn’t a Medicaid expert, lawyer or medical professional. But she still thinks Connecticut legislators need her input when they consider bills affecting people like her — the roughly 18,000 residents who live in the state’s nursing homes. With help and encouragement from Connecticut’s Long Term Care Ombudsman Program, Bausch signed up and testified …

Zooming Into the Statehouse: Nursing Home Residents Use New Digital Skills to Push for Changes Read More »

From Rotten Teeth to Advanced Cancer, Patients Feel the Effects of Treatment Delays

With medical visits picking up again among patients vaccinated against covid-19, health providers are starting to see the consequences of a year of pandemic-delayed preventive and emergency care as they find more advanced cancer and rotting and damaged teeth, among other ailments. This story also ran on The Washington Post. It can be republished for …

From Rotten Teeth to Advanced Cancer, Patients Feel the Effects of Treatment Delays Read More »

IQVIA pays Quest Diagnostics $760M to get full control of central lab joint venture

IQVIA has acquired Quest Diagnostics’ minority stake in Q2 Solutions, a central laboratory services joint venture the two companies formed in 2015. But Quest will remain a preferred provider of lab testing services under an agreement with Q2.

Connecticut Is Doling Out Vaccines Based Strictly on Age. It’s Simpler, but Is it Fair?

With covid vaccines expected to remain scarce into early spring, Connecticut has scrapped its complicated plans to prioritize immunizations for people under 65 with certain chronic conditions and front-line workers. Instead, the state will primarily base eligibility on age. Gov. Ned Lamont pointed to statistics showing the risk of death and hospitalization from covid-19 rises …

Connecticut Is Doling Out Vaccines Based Strictly on Age. It’s Simpler, but Is it Fair? Read More »

Geography Is Destiny: Dentists’ Access to Covid Shots Depends on Where They Live

Use Our Content It can be republished for free. Dr. Monte Junker, an Oregon dentist, is waiting for his turn to get vaccinated for covid even though he considers himself a front-line health worker. “If they offered it to me today, I would be there,” he said. In December, just before the first vaccines were …

Geography Is Destiny: Dentists’ Access to Covid Shots Depends on Where They Live Read More »

Purdue to plead guilty, pay $8.3B deal to resolve opioid charges

In addition to monetary damages and the guilty pleas, the government is seeking to transform the maker of OxyContin into a public benefit company that would fund efforts to curb opioid abuse and give away drugs to prevent overdose deaths.